Unknown

Dataset Information

0

Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.


ABSTRACT: Inhibition of the myostatin signaling pathway is emerging as a promising therapeutic means to treat muscle wasting and degenerative disorders. Activin type IIB receptor (ActRIIB) is the putative myostatin receptor, and a soluble activin receptor (ActRIIB-Fc) has been demonstrated to potently inhibit a subset of transforming growth factor (TGF)-? family members including myostatin. To determine reliable and valid biomarkers for ActRIIB-Fc treatment, we assessed gene expression profiles for quadriceps muscles from mice treated with ActRIIB-Fc compared with mice genetically lacking myostatin and control mice. Expression of 134 genes was significantly altered in mice treated with ActRIIB-Fc over a 2-wk period relative to control mice (fold change > 1.5, P < 0.001), whereas the number of significantly altered genes in mice treated for 2 days was 38, demonstrating a time-dependent response to ActRIIB-Fc in overall muscle gene expression. The number of significantly altered genes in Mstn(-/-) mice relative to control mice was substantially higher (360), but for most of these genes the expression levels in the 2-wk treated mice were closer to the levels in the Mstn(-/-) mice than in control mice (P < 10?³?). Expression levels of 30 selected genes were further validated with quantitative real-time polymerase chain reaction (qPCR), and a correlation of ? 0.89 was observed between the fold changes from the microarray analysis and the qPCR analysis. These data suggest that treatment with ActRIIB-Fc results in overlapping but distinct gene expression signatures compared with myostatin genetic mutation. Differentially expressed genes identified in this study can be used as potential biomarkers for ActRIIB-Fc treatment, which is currently in clinical trials as a therapeutic agent for muscle wasting and degenerative disorders.

SUBMITTER: Rahimov F 

PROVIDER: S-EPMC3092338 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.

Rahimov Fedik F   King Oliver D OD   Warsing Leigh C LC   Powell Rachel E RE   Emerson Charles P CP   Kunkel Louis M LM   Wagner Kathryn R KR  

Physiological genomics 20110125 8


Inhibition of the myostatin signaling pathway is emerging as a promising therapeutic means to treat muscle wasting and degenerative disorders. Activin type IIB receptor (ActRIIB) is the putative myostatin receptor, and a soluble activin receptor (ActRIIB-Fc) has been demonstrated to potently inhibit a subset of transforming growth factor (TGF)-β family members including myostatin. To determine reliable and valid biomarkers for ActRIIB-Fc treatment, we assessed gene expression profiles for quadri  ...[more]

Similar Datasets

2011-02-04 | GSE25306 | GEO
2011-02-04 | E-GEOD-25306 | biostudies-arrayexpress
| S-EPMC6400483 | biostudies-literature
| S-EPMC4279095 | biostudies-literature
| S-EPMC5702601 | biostudies-literature
| S-EPMC6770556 | biostudies-literature
| S-EPMC5509431 | biostudies-literature
| S-EPMC2383948 | biostudies-literature
| S-EPMC4091925 | biostudies-literature
| S-EPMC8621074 | biostudies-literature